B-cell receptor populations specific for Neisseria meningitidis capsular polysaccharides of serogroups A, C, W, and Y (BCR (MenACWY-specific))

The B-cell receptor (BCR) populations specific for Neisseria meningitidis capsular polysaccharides of serogroups A, C, W, and Y are the primary immunological targets for quadrivalent meningococcal vaccines (MenACWY) [NIH, CDC]. These receptors are membrane-bound immunoglobulins on the surface of B lymphocytes that specifically recognize the unique chemical structures of the capsular polysaccharides (CPS) from these four pathogenic serogroups [NIH]. Upon binding to these antigens, the BCRs initiate signaling cascades, such as the NF-κB pathway, that lead to B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells and long-lived memory B cells [SciSpace, RSC]. In the case of conjugate vaccines, the BCR also facilitates the internalization of the polysaccharide-protein complex for processing and presentation to T-helper cells via MHC class II, which is essential for inducing a robust and persistent immune response, especially in infants [RSC, ACS]. The successful stimulation of these BCR populations is critical for generating protective bactericidal antibodies, measured by Serum Bactericidal Activity (SBA) titers, which prevent invasive meningococcal disease, including meningitis and septicemia [SciSpace, NIH]. Furthermore, the diversity and affinity of these BCR populations determine the breadth and duration of the protective immune response following vaccination [NIH, TandfOnline].

Other names

Meningococcal polysaccharide-specific B-cell receptorsMenACWY-specific BCRsAnti-capsular B-cell receptorsNeisseria meningitidis serogroup A, C, W, and Y capsular polysaccharide-specific B-cell receptorsMeningococcal ACWY-specific B-cell receptors

Antigen binding to the B-cell receptor (BCR) triggers B-cell activation and differentiation [NIH, RSC]. For plain polysaccharide vaccines, BCR cross-linking leads to T-cell independent activation [SciSpace]. For conjugate vaccines, the BCR mediates the uptake of the polysaccharide-protein conjugate, allowing for T-cell help, which results in high-affinity antibody production and the formation of memory B cells [ACS, NIH].